HC3 is closely tracking hacktivist groups which have previously affected a wide range of countries and industries, including the United States Healthcare and Public Health (HPH) sector.
Once the emergency ends, Medicare beneficiaries generally will face out-of-pocket costs for at-home testing and all treatment. However, vaccines will continue to be covered at no cost, as will testing ordered by a health care provider.
Medtronic is recalling the Mahurkar Acute Dual Lumen High Flow (13.5 French) Hemodialysis Catheters due to a potential catheter hub defect that may cause leaks across the catheter’s tubes.
Exela Pharma Sciences, LLC, (Exela) is expanding their recall, adding fourteen (14) lots to the ongoing voluntary recall of forty-nine (49) lots of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial, 20-count carton.
The FDA is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab).
Dialysis Providers: The Centers for Medicare & Medicaid Services (CMS) End Stage Renal Disease Quality Incentive Program (ESRD QIP) reminds you that the payment year (PY) 2023 ESRD QIP preview period o
The Centers for Medicare & Medicaid Services (CMS) issued a final rule that updates Medicare enrollment and eligibility rules to expand coverage for people with Medicare and advance health equity.
This announcement is to notify dialysis facilities that the Centers for Medicare & Medicaid Services (CMS) has extended the End Stage Renal Disease (ESRD) Quality Reporting System (EQRS) clinical data submission deadline for August 2022 data b
Published: October 13, 2022
Exela Pharma Sciences, LLC, (Exela) is voluntarily recalling 49 lots of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial, 20- count carton, to the consumer level.